[{"id":"b3ec16de-b06c-4b4e-97bd-502739a6230d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02664935","created_at":"2021-01-18T12:59:26.753Z","updated_at":"2025-02-25T14:36:10.262Z","phase":"Phase 2","brief_title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02664935","lead_sponsor":"University of Birmingham","biomarkers":" NKX2-1 • TP63","pipe":"","alterations":" ","tags":["NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-13"},{"id":"1a362148-ee5c-47c2-86f4-0b3ccd6e171d","acronym":"BGB-900-2001-IIT","url":"https://clinicaltrials.gov/study/NCT04734262","created_at":"2021-02-02T15:52:16.111Z","updated_at":"2024-07-02T16:35:28.564Z","phase":"Phase 2","brief_title":"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT04734262 - BGB-900-2001-IIT","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • sitravatinib (MGCD516)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-11-20"},{"id":"2066901f-478a-4546-85e8-5d533f8446bb","acronym":"SAPPHIRE","url":"https://clinicaltrials.gov/study/NCT03906071","created_at":"2021-01-18T19:13:45.837Z","updated_at":"2024-07-02T16:35:32.194Z","phase":"Phase 3","brief_title":"Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03906071 - SAPPHIRE","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • sitravatinib (MGCD516)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 532","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 03/20/2023","primary_completion_date":" 03/20/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-10-23"},{"id":"15408d6a-1840-4968-924b-1d11cb2d1ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03680521","created_at":"2021-05-19T21:56:08.066Z","updated_at":"2024-07-02T16:35:34.782Z","phase":"Phase 2","brief_title":"Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT03680521","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • CD27","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PD-1 • CD4 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sitravatinib (MGCD516)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 04/27/2020","primary_completion_date":" 04/27/2020","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2023-10-04"},{"id":"c28b82e1-c81b-4d49-95a1-2405f6e69519","acronym":"SNOW","url":"https://clinicaltrials.gov/study/NCT03575598","created_at":"2021-01-18T17:35:35.496Z","updated_at":"2025-02-25T14:27:11.326Z","phase":"Phase 1","brief_title":"Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study","source_id_and_acronym":"NCT03575598 - SNOW","lead_sponsor":"University Health Network, Toronto","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sitravatinib (MGCD516)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/30/2018","start_date":" 08/30/2018","primary_txt":" Primary completion: 02/18/2020","primary_completion_date":" 02/18/2020","study_txt":" Completion: 02/18/2020","study_completion_date":" 02/18/2020","last_update_posted":"2023-07-27"},{"id":"e169cd11-81c4-4db1-ad07-f2bdd68ad095","acronym":"","url":"https://clinicaltrials.gov/study/NCT03015740","created_at":"2021-01-18T14:50:27.848Z","updated_at":"2024-07-02T16:35:49.251Z","phase":"Phase 1/2","brief_title":"Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03015740","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sitravatinib (MGCD516)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 04/23/2017","start_date":" 04/23/2017","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2023-05-01"},{"id":"14691476-262f-4a49-a891-fa28962412ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02219711","created_at":"2021-01-17T17:38:13.217Z","updated_at":"2024-07-02T16:35:54.001Z","phase":"Phase 1","brief_title":"Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer","source_id_and_acronym":"NCT02219711","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sitravatinib (MGCD516)"],"overall_status":"Completed","enrollment":" Enrollment 193","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/27/2022","study_completion_date":" 04/27/2022","last_update_posted":"2023-03-06"},{"id":"b3041ff0-8ab9-4092-aa19-1afc64e1d3d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05419817","created_at":"2022-06-15T16:54:57.279Z","updated_at":"2025-02-25T14:17:03.288Z","phase":"Phase 2","brief_title":"Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System","source_id_and_acronym":"NCT05419817","lead_sponsor":"Haider Mahdi","biomarkers":" MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sitravatinib (MGCD516)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-02-27"},{"id":"d60fdd3c-17bc-4c33-97df-ff5ab3310602","acronym":"BGB-900-2002-IIT","url":"https://clinicaltrials.gov/study/NCT05104801","created_at":"2021-11-03T13:53:10.979Z","updated_at":"2024-07-02T16:36:21.582Z","phase":"Phase 2","brief_title":"Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT05104801 - BGB-900-2002-IIT","lead_sponsor":"Beijing Cancer Hospital","biomarkers":" BRAF • TIGIT","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • sitravatinib (MGCD516)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-11-03"}]